Adoptive T-Cell Immunotherapy

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Epstein-Barr virus (EBV) drives various cancers through distinct latent antigen expression patterns.
• Tumor immunogenicity and T-cell therapy response are significantly influenced by viral antigen expression.
• Adoptive transfer of EBV-specific T cells (EBVSTs) is highly effective for posttransplant lymphoproliferative disease (PTLD) post-hematopoietic stem cell transplantation (HSCT).

Purpose of the Study:

• To review the clinical efficacy and advancements in EBV-specific T-cell (EBVST) therapies for EBV-associated malignancies.
• To explore strategies for overcoming challenges in treating type 2 latency EBV tumors.
• To highlight the potential of genetically engineered T cells in enhancing antitumor immunity.

Main Methods:

• Review of clinical data on EBVST efficacy in PTLD and other EBV-associated diseases.
• Analysis of strategies involving T cells targeting type 2 latency antigens (LMP1, LMP2, EBNA1, BARF1).
• Evaluation of genetic engineering techniques to enhance T-cell function (e.g., drug resistance, cytokine support, improved trafficking).

Main Results:

• EBVSTs demonstrate exceptional efficacy, safety, and durability in PTLD post-HSCT.
• Multispecific virus-specific T cells (VSTs) and "off-the-shelf" products increase accessibility and enable urgent treatment.
• Targeting type 2 latency antigens and employing genetic engineering show promise for overcoming immune evasion in challenging tumors.

Conclusions:

• EBVSTs are a safe and durable therapeutic option for EBV-associated diseases.
• Ongoing innovations in T-cell engineering and antigen targeting will broaden VST applicability.
• Cell therapies hold significant potential for treating EBV-associated and other cancers.